Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Hemasphere. 2022 May 25;6(6):e729. doi: 10.1097/HS9.0000000000000729. eCollection 2022 Jun.
No abstract available